Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia

NCT00401973 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00401973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
September 30, 2008
Enrollment
199 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorders, schizophrenia